ResearcherSecond Military Medical UniversityNo recent work listed
Shengnan Ren
Matched on ORCID iD 0000-0001-7869-141X; OpenAlex author ID A5102828693. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 4
- Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Rad… Co-author DOI 10.1155/2022/6528865↗
- Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and autoimmune pancreatitis. Co-author DOI 10.1007/s00330-021-07778-0↗
- Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. Co-author DOI 10.1186/s40644-020-00301-6↗
- Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereo… First author DOI 10.1097/md.0000000000015064↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Changjing Zuo · 4 shared papers, 2019–2022 · strength 0.52
- Paper Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic… DOI 10.1155/2022/6528865↗
- Paper Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated wi… DOI 10.1186/s40644-020-00301-6↗
- Paper Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and auto… DOI 10.1007/s00330-021-07778-0↗
- Chao Cheng · 2 shared papers, 2021–2022 · strength 0.28
- Paper Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic… DOI 10.1155/2022/6528865↗
- Paper Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and auto… DOI 10.1007/s00330-021-07778-0↗
- Xiaodong Yang · 2 shared papers, 2021–2022 · strength 0.28
- Paper Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic… DOI 10.1155/2022/6528865↗
- Paper Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and auto… DOI 10.1007/s00330-021-07778-0↗
- Zhaobang Liu · 2 shared papers, 2021–2022 · strength 0.28
- Paper Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic… DOI 10.1155/2022/6528865↗
- Paper Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and auto… DOI 10.1007/s00330-021-07778-0↗
- Anyu Zhang · 2 shared papers, 2019–2020 · strength 0.24
- Paper Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated wi… DOI 10.1186/s40644-020-00301-6↗
- Paper Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer und… DOI 10.1097/md.0000000000015064↗
- Xiaofei Zhu · 2 shared papers, 2019–2020 · strength 0.24
- Paper Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated wi… DOI 10.1186/s40644-020-00301-6↗
- Paper Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer und… DOI 10.1097/md.0000000000015064↗
- Fei Wang · 1 shared paper, 2022 · strength 0.16
- Huojun Zhang · 1 shared paper, 2020 · strength 0.13
- Gaofeng Sun · 1 shared paper, 2021 · strength 0.12
- Lingong Jiang · 1 shared paper, 2019 · strength 0.10
- Xiao Li · 1 shared paper, 2019 · strength 0.10
- Yuan Yuan Ma · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.